Investigation raises new concerns over landmark trial for top selling anti-platelet drug
Ticagrelor costs the US over $750m a year, but a BMJ investigation raises fresh doubts over the trustworthiness of the major clinical trial that brought the drug to market An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval ...